Vision statement

Clinuvel aims to be a global leader in pharmaceutical development and maintain its expertise on the interaction of light and skin. We continually strive to further develop and share knowledge on all aspects related to photoprotection, environmental factors and related risks; particularly in relation to pigmentation disorders, light-related skin diseases and skin cancer.

Clinuvel’s objectives are to serve patients, physicians and shareholders in the process of its product development. To this end, the company collaborates with all leading regulatory authorities to best serve and protect those dedicated to the company’s success.

Read the Latest Blog Posts

Image

Hang in there! Take back control!...

We recently invited Richard Roosenboom to share his experiences as a parent of a child with a rare disease.... Read more...

Image

Too rare to diagnose: Hydroa Vacc...

We recently invited Richard Roosenboom to share his experiences as a parent of a child with a rare disease.... Read more...

Image

Top five sun and skin myths (part...

Myth 4: I need lots of sun exposure to create vitamin D Vitamin D is a contentious topic in modern... Read more...

Watch the Latest Videos

Part Four - The impact of Erythro...

Mikey's quality of life, like all patients with Erythropoietic Protoporphyria (EPP), is severely affected. Severe pain f... Watch now

Quick! I need Sunburn Relief! Rem...

There are many remedies available to help provide relief from the symptoms of sunburn. Treatment of sunburn can include:... Watch now

Understanding Vitiligo - Causes &...

Vitiligo is a common pigmentary disorder in which the pigment producing cells of the skin (melanocytes) are absent or do... Watch now

JoomlaXTC K2 Content Wall - Copyright 2010 Monev Software LLC

Clinuvel in Focus

Company History

The technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology an... Read more

JoomlaXTC K2 Content Wall - Copyright 2010 Monev Software LLC